ChemoCentryx reported a substantial increase in revenue and achieved net income for the quarter, primarily driven by contract revenue recognition. Management's optimistic outlook on their clinical pipeline and upcoming FDA decisions further supports a positive short-term sentiment for the stock.

[1]